Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

WSA Speaks to Three Companies on the Rise

CLRO, SCRCQ

Wall Street Analyzer's CEO Interview Series

NEW YORK, NY--(Marketwired - December 02, 2014) - ClearOne (NASDAQ: CLRO) CEO Zee Hakimoglu discussed the company's favorable Q3 results reporting 27% revenue growth from last year with solid profitability. She outlined ClearOne's products and patents and talked about two recent acquisitions and how these acquisitions have positioned ClearOne favorably in their traditional audio conferencing market as well as in the emerging media collaboration market. 

ACCESS FULL INTERVIEW

ScripsAmerica (OTCBB: SCRC) CEO Bob Schneiderman discussed the company's specialty pharmacy, which opened earlier this year, and illustrated how they grew their revenue from $125,000 a month to $5.6 million, in October. He talked about the company's compounding product and some of the key benefits. Mr. Schneiderman also went over ScripsAmerica's recent partnerships and expansion plans, noting that they hope to launch their new RapiMed product in Asia. In addition, he mentioned the company's plans to uplist to a major exchange.

ACCESS FULL INTERVIEW

Rich Pharmaceuticals (OTCQB: RCHA) CEO Ben Chang spoke about the company's submission of an IND (investigational new drug) application to the FDA for the treatment of acute myelocytic leukemia (AML) and myelodysplastic syndrome (MDS) on their lead compound, RP-323. He also provided an update on the company's recent financing, identified industry trends that the company is currently monitoring, and provided some key factors that set the company apart from the rest of the pharmaceutical industry. Rounding out the interview, Mr. Chang provided an overview of the management team, outlined goals for the upcoming year, and discussed why he feels RCHA is undervalued.

ACCESS FULL INTERVIEW

About WSA:

The Wall Street Analyzer's aim is to provide investors with the tools they need to make informed decisions on holding stocks. Our staff includes a mix of financial professionals and media savvy individuals whose experiences bring the best talent from both ends of the spectrum. On one hand our financial experience gives us the ability to identify promising, off the grid companies before the rest of the market uncovers them, and on the other hand our media experience allows us to produce interviews, which appeal to a larger audience. We provide a format in which more individual investors can understand a featured companies' upside. Our philosophy is to turn stock tickers into stories, ideas into headlines, and technical and financial data into easier to understand data. Visit: http://www.wallstreetanalyzer.com

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by phrases such as SLWF or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, such statements in this release that describe the company's business strategy, outlook, objectives, plans, intentions, or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. These risks and uncertainties include, among other things, product price volatility, product demand, market competition, and risk inherent in the operations of a company. We assume no obligation to update any written or oral forward-looking statement made by us or on our behalf as a result of new information, future events or other factors.

Contact:

ClearOne, Inc
Jimmie Owsley
ClearOne Marketing
1-801-9757200
Email contact

For ScripsAmerica
Seal Point Consulting
888-959-7095

Rich Pharmaceuticals
Ben Chang
CEO
424-230-7001 EXT 105

WSA
347-529-5734
Email contact



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today